Intercure - Asset Resilience Ratio
Intercure (INCR) has an Asset Resilience Ratio of 0.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check INCR capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Intercure's Asset Resilience Ratio has changed over time. See INCR equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Intercure's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see INCR market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA209.00K | 0.03% |
| Total Liquid Assets | ILA209.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Intercure maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Intercure Industry Peers by Asset Resilience Ratio
Compare Intercure's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Intercure (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Intercure.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.03% | ILA209.00K ≈ $560.32 |
ILA690.55 Million ≈ $1.85 Million |
-0.01pp |
| 2024-12-31 | 0.04% | ILA333.00K ≈ $892.76 |
ILA762.57 Million ≈ $2.04 Million |
+0.02pp |
| 2023-12-31 | 0.02% | ILA187.00K ≈ $501.34 |
ILA786.61 Million ≈ $2.11 Million |
+0.00pp |
| 2022-12-31 | 0.02% | ILA205.00K ≈ $549.60 |
ILA958.01 Million ≈ $2.57 Million |
-0.03pp |
| 2021-12-31 | 0.05% | ILA330.00K ≈ $884.72 |
ILA686.32 Million ≈ $1.84 Million |
-0.07pp |
| 2020-12-31 | 0.12% | ILA376.00K ≈ $1.01K |
ILA326.27 Million ≈ $874.72K |
+0.05pp |
| 2019-12-31 | 0.06% | ILA177.00K ≈ $474.53 |
ILA282.23 Million ≈ $756.66K |
-0.62pp |
| 2018-12-31 | 0.68% | ILA246.00K ≈ $659.52 |
ILA35.92 Million ≈ $96.30K |
-0.65pp |
| 2017-12-31 | 1.34% | ILA319.75K ≈ $857.25 |
ILA23.95 Million ≈ $64.20K |
-0.27pp |
| 2016-12-31 | 1.61% | ILA446.20K ≈ $1.20K |
ILA27.73 Million ≈ $74.35K |
-7.36pp |
| 2015-12-31 | 8.97% | ILA1.13 Million ≈ $3.04K |
ILA12.62 Million ≈ $33.84K |
-54.16pp |
| 2014-12-31 | 63.13% | ILA1.67 Million ≈ $4.47K |
ILA2.64 Million ≈ $7.08K |
+12.34pp |
| 2013-12-31 | 50.79% | ILA3.13 Million ≈ $8.39K |
ILA6.16 Million ≈ $16.53K |
-10.82pp |
| 2012-12-31 | 61.61% | ILA8.95 Million ≈ $24.00K |
ILA14.53 Million ≈ $38.95K |
+61.30pp |
| 2011-12-31 | 0.31% | ILA9.00K ≈ $24.13 |
ILA2.92 Million ≈ $7.83K |
-7.28pp |
| 2010-12-31 | 7.59% | ILA100.00K ≈ $268.10 |
ILA1.32 Million ≈ $3.53K |
-- |
About Intercure
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in… Read more